lornoxicam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
anti-inflammatory, isoxicam derivatives 1609 70374-39-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lornoxicam
  • chlortenoxicam
  • lorcam
  • xefocam
  • Molecular weight: 371.81
  • Formula: C13H10ClN3O4S2
  • CLOGP: 2.34
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 99.60
  • ALOGS: -3.93
  • ROTB: 2

Drug dosage:

DoseUnitRoute
12 mg O
12 mg P
12 mg R

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.14 L/kg Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
BA (Bioavailability) 100 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.349 Moderate 0.69
caco2-efflux Caco-2 efflux ratio (BA/AB) 9.099 Moderate 0.69
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 86.696 10^-6 cm/s Moderate 0.69
dh-clint Dog hepatocyte intrinsic clearance 7.621 uL/min/10^6 cells Moderate 0.69
dppb Dog plasma protein binding (% unbound) 1.580 % Moderate 0.69
fcs-ppb Fetal calf serum protein binding (% unbound) 1.390 % Moderate 0.69
herg hERG pIC50 4.451 pIC50 Moderate 0.69
hh-clint Human hepatocyte intrinsic clearance 10.940 uL/min/10^6 cells Moderate 0.69
hlm-clint Human liver microsomal intrinsic clearance 6.486 uL/min/mg protein Moderate 0.69
hppb Human plasma protein binding (% unbound) 0.310 % Moderate 0.69
kinase-safety-class ACVR2A,ACVR2B,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,GRK3,GSK3B,ITK,JAK1,JAK2,KIT,MAP3K1,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 54
kinase-selectivity-class ACVR2A,AURKB,AURKC,AXL,BRAF,CAMK2D,CDK9,DDR1,DYRK1B,ERBB2,GRK2,MAP2K3,MAP2K6,MAPK12,MAPK7,MARK4,PRKDC,SIK2,STK33,SYK,TEK,TTK 22
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 12.972 Moderate 0.69
mh-clint Mouse hepatocyte intrinsic clearance 12.050 Moderate 0.69
mppb Mouse plasma protein binding (% unbound) 1.620 Moderate 0.69
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.948 Moderate 0.69
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.66
pppb Pig plasma protein binding (% unbound) 1.030 % Moderate 0.69
rh-clint Rat hepatocyte intrinsic clearance 14.322 uL/min/10^6 cells Moderate 0.69
rh-fuinc Rat hepatocyte fraction unbound in incubation 73.320 % Moderate 0.69
rppb Rat plasma protein binding (% unbound) 0.350 % Moderate 0.69
solubility-dd Solubility at pH 7.4 in DMSO 734.514 uM Moderate 0.69

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angioedema 67.53 52.36 21 429 64855 90563142

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anorgasmia 56.21 44.16 10 891 1636 110586762
Drug interaction 49.31 44.16 37 864 500146 110088252
Angioedema 45.32 44.16 20 881 98480 110489918

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M01AC05 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Oxicams
MeSH PA D000700 Analgesics
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018501 Antirheumatic Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D018712 Analgesics, Non-Narcotic
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory drug
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35481 non-narcotic analgesic
CHEBI has role CHEBI:35493 antipyretic

Related Drugs by ATC class:

M01AC Oxicams 4 drugs
droxicammeloxicampiroxicamtenoxicam

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pain indication 22253000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.98 acidic
pKa2 8.43 acidic
pKa3 5.18 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D01866 KEGG_DRUG
C0055477 UMLSCUI
CHEBI:31783 CHEBI
CHEMBL1569487 ChEMBL_ID
DB06725 DRUGBANK_ID
C059451 MESH_SUPPLEMENTAL_RECORD_UI
54690031 PUBCHEM_CID
6233 INN_ID
ER09126G7A UNII
20890 RXNORM
007785 NDDF
391655005 SNOMEDCT_US
412013008 SNOMEDCT_US
ER09126G7A INXIGHT DRUGS

Pharmaceutical products:

None